CLAIMS

[Claim 1]

Calcium salt of 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid, or pharmaceutically acceptable hydrate thereof.

[Claim 2]

The pharmaceutically acceptable hydrate of calcium salt of 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid according to claim 1.

[Claim 3]

The calcium salt of 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid according to claim 1.

[Claim 4]

A crystalline form of the calcium salt according to claim 1 or 3 or the pharmaceutically acceptable hydrate according to claim 1 or 2, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 4.8°, 8.7°, 9.7°, 15.2° and 18.5°, wherein the X-ray powder diffraction diagram is obtained by using Cu Kα radiation.

[Claim 5]

A crystalline form according to claim 4, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 4.8°, 8.7°, 9.7°, 11.1°, 15.2°, 16.0°, 18.1°, 18.5°, and 23.4°, wherein the X-ray powder diffraction diagram is obtained by using Cu Kα radiation.

[Claim 6]

A pharmaceutical composition containing at least one of the calcium salt according to claim 1 or 3, the pharmaceutically acceptable hydrate according to claim 1 or 2, and the crystalline form according to claim 4 or 5, as an active ingredient.